Vitaccess Real MG Registry

NCT06064461 · tracked via the Priya Life Science USA tracker

Sponsor

Vitaccess Ltd

Phase

Observational

Started

2024-07-31

Last updated

2025-07-29

Condition(s) studied

Myasthenia Gravis

Study summary

Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 600 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from medical records.

Patients will be recruited at clinical sites in all participating countries. In the US only, patients can additionally be recruited via community neurologists or direct-to-patient recruitment.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adult (age ≥18 years) with a clinically-confirmed diagnosis of myasthenia gravis (MG). * Resident in one of the scope countries. * Access to a smartphone/tablet/computer/laptop * Willing and able to provide informed consent in their local language to take part in the study. Exclusion Criteria: * Participation in a clinical trial at the time of study enrolment.

Primary outcome measure(s)

The Vitaccess Real MG Registry — 10 years
A patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life.

Trial sites (8)

Facility	City	Region	Status
UCI Health	Orange	California	Recruiting
HSHS St. Elizabeth's Hospital	O'Fallon	Illinois	Recruiting
UK HealthCare - University of Kentucky	Lexington	Kentucky	Recruiting
Neurology Associates of South Jersey	Lumberton	New Jersey	Recruiting
Medical University South Carolina	Charleston	South Carolina	Recruiting
University of Texas Health Science Center at Houston	Houston	Texas	Recruiting
Vitaccess Ltd	London	London	Recruiting
University Hospitals Birmingham	Birmingham	United Kingdom	Recruiting

Other trials for the same condition

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis Active, not recruiting

Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment Recruiting

SP Thoracic IDE Study Active, not recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis Recruiting

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06064461 on ClinicalTrials.gov ↗ ← All trials in the USA